FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly ...

FibroBiologics (FBLG) announced the filing of a patent application covering methods for treatment of splenomegaly using a cell-based ...

GSK’s $1.9 billion takeover of Sierra Oncology has delivered the first new product, with the EU approval of Omjjara for the treatment of enlarged spleen (splenomegaly) or symptoms in adult ...

the company provides fedratinib according to the commercial arrangement. This recommendation is not intended to affect treatment with fedratinib that was started in the NHS before this guidance was ...

There is a simple discount patient access scheme for fedratinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Splenomegaly resulting from portal hypertension can be caused by cirrhosis, hepatic venous outflow tract obstruction and extrahepatic portal vein obstruction. Both cirrhosis and hepatic venous ...

A previous history of infectious mononucleosis or the presence of recent cold symptoms had no significant affect on spleen size. In more than 7% of athletes, baseline spleen size met current criteria ...